



Seres Therapeutics to Present at the Cowen and Company 36th Annual Health Care Conference

March 2, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 2, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced it will present at the Cowen and Company 36th Annual Health Care Conference in Boston on Wednesday, March 9. The presentation will take place in the Provincetown Room at the Boston Marriott Copley Place at 10 a.m. EST.

Live audio webcast will be available under the Investors and Media section of Seres' website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome characterized by an increased presence of pathogenic bacterial species, where the natural state of bacterial diversity is imbalanced. Seres' most advanced program, SER-109, has successfully completed a Phase 1b/2 study demonstrating a clinical benefit in patients with recurring *Clostridium difficile* infection (CDI) and is currently being evaluated in a Phase 2 study in recurring CDI. The FDA has granted SER-109 Orphan Drug, as well as Breakthrough Therapy, designations. Seres' second clinical candidate, SER-287, is being evaluated in a Phase 1b study in patients with mild-to-moderate ulcerative colitis (UC).



View source version on businesswire.com: <http://www.businesswire.com/news/home/20160302005202/en/>

Source: Seres Therapeutics, Inc.

IR Contact:

Seres Therapeutics
Carlo Tanzi, Ph.D., 617-203-3467
Head of Investor Relations and Corporate Communications
Ctanzi@serestherapeutics.com

or

PR Contact:

Ten Bridge Communications
Dan Quinn, 781-475-7974
Dan@tenbridgecommunications.com